The DOI matches its OpenAlex record; 72 of the 72 references it cites were found in a registry or an index.
Dry Powder Inhaler Formulation
Abstract
A drug product combines pharmacologic activity with pharmaceutical properties. Desirable performance characteristics are physical and chemical stability, ease of processing, accurate and reproducible delivery to the target organ, and availability at the site of action. For the dry powder inhaler (DPI), these goals can be met with a suitable powder formulation, an efficient metering system, and a carefully selected device. This review focuses on the DPI formulation and development process. Most DPI formulations consist of micronized drug blended with larger carrier particles, which enhance flow, reduce aggregation, and aid in dispersion. A combination of intrinsic physicochemical properties, particle size, shape, surface area, and morphology affects the forces of interaction and aerodynamic properties, which in turn determine fluidization, dispersion, delivery to the lungs, and deposition in the peripheral airways. When a DPI is actuated, the formulation is fluidized and enters the patient's airways. Under the influence of inspiratory airflow, the drug particles separate from the carrier particles and are carried deep into the lungs, while the larger carrier particles impact on the oropharyngeal surfaces and are cleared. If the cohesive forces acting on the powder are too strong, the shear of the airflow may not be sufficient to separate the drug from the carrier particles, which results in low deposition efficiency. Advances in understanding of aerosol and solid state physics and interfacial chemistry are moving formulation development from an empirical activity to a fundamental scientific foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adsorption of Gases in Multimolecular Layers
Brunauer, S., Emmett, P. H., & Teller, E. (1938) · Journal of the American Chemical Society · doi:10.1021/ja01269a023 · Cited by 28,156
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Intermolecular and Surface Forces
(2011) · Intermolecular and Surface Forces · doi:10.1016/b978-0-12-391927-4.10024-6 · Cited by 16,923
Binnig, G., Quate, C. F., & Gerber, C. (1986) · Physical Review Letters · doi:10.1103/physrevlett.56.930 · Cited by 14,762
Perry's chemical engineers' handbook
(2008) · Choice Reviews Online · doi:10.5860/choice.45-4393 · Cited by 10,121
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids
Moulton, B., & Zaworotko, M. J. (2001) · Chemical Reviews · doi:10.1021/cr9900432 · Cited by 6,395
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Handbook of Pharmaceutical Excipients
Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (1994) · Cited by 3,493
Multiphase Flows with Droplets and Particles
Crowe, C. T., Schwarzkopf, J. D., Sommerfeld, M., & Tsuji, Y. (2011) · doi:10.1201/b11103 · Cited by 3,076
Multiphase Flow And Fluidization: Continuum And Kinetic Theory Descriptions
Gidaspow, D. (2012) · Cited by 2,114
Labiris, N. R., & Dolovich, M. B. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01892.x · Cited by 1,245
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,174
Particle design using supercritical fluids: Literature and patent survey
Jung, J., & Perrut, M. (2001) · The Journal of Supercritical Fluids · doi:10.1016/s0896-8446(01)00064-x · Cited by 1,141
Polymorphism in Pharmaceutical Solids
(2018) · CRC Press eBooks · doi:10.3109/9781420073225 · Cited by 1,099
Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines
Dolovich, M. B., Ahrens, R. C., Hess, D. R., Anderson, P., Dhand, R., Rau, J. L., Smaldone, G. C., & Guyatt, G. (2005) · Chest · doi:10.1378/chest.127.1.335 · Cited by 794
Bates, D. V., Fish, B., Hatch, T. F., Mercer, T. T., & Morrow, P. E. (1966) · PubMed · Cited by 771
Electrical low pressure impactor
Keskinen, J., Pietarinen, K., & Lehtimäki, M. (1992) · Journal of Aerosol Science · doi:10.1016/0021-8502(92)90004-f · Cited by 637
Desiraju, G. R. (2001) · Nature · doi:10.1038/35086640 · Cited by 602
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability
Giraud, V., & Roche, N. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00218402 · Cited by 538
Respiratory Drug Delivery (1989)
Byron, P. R. (2018) · CRC Press eBooks · doi:10.4324/9780203710456 · Cited by 449
Inhaled Corticosteroids for Asthma Therapy
Cochrane, M. G., Bala, M. V., Downs, K. E., Mauskopf, J., & Ben-Joseph, R. H. (2000) · Chest · doi:10.1378/chest.117.2.542 · Cited by 428
Correlation of Drug Absorption with Molecular Surface Properties
Palm, K., Luthman, K., Unge, A.-L., Strandlund, G., & Artursson, P. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950285r · Cited by 412
Physical Characterization of Pharmaceutical Solids
Brittain, H. G., Bogdanowich, S. J., Bugay, D. E., DeVincentis, J., Lewen, G., & Newman, A. W. (1991) · Pharmaceutical Research · doi:10.1023/a:1015888520352 · Cited by 344
Evolution of dry powder inhaler design, formulation, and performance
NEWMAN, S. P., & BUSSE, W. W. (2002) · Respiratory Medicine · doi:10.1053/rmed.2001.1276 · Cited by 340
Alternative routes of insulin delivery
Owens, D. R., Zinman, B., & Bolli, G. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01076.x · Cited by 332
Drug delivery to the respiratory tract using dry powder inhalers
Timsina, M. P., Martin, G. P., Marriott, C., Ganderton, D., & Yianneskis, M. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90070-1 · Cited by 325
Pharmaceutical Inhalation Aerosol Technology
(2003) · CRC Press eBooks · doi:10.1201/9780203912898 · Cited by 292
Pharmaceutical profiling in drug discovery
Kerns, E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02649-7 · Cited by 288
The Inhalation of Drugs: Advantages and Problems
Rau, J. L. (2005) · Respiratory Care · doi:10.4187/respcare.05500367 · Cited by 279
Profiling drug-like properties in discovery research
Di, L., & Kerns, E. H. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00055-3 · Cited by 278
Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance
Chew, N. Y. K., & Chan, H.-K. (2001) · Pharmaceutical Research · doi:10.1023/a:1013082531394 · Cited by 250
(D) Routes of delivery: Case studies
Patton, J. S., & Platz, R. M. (1992) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(92)90002-8 · Cited by 249
Absorption Classification of Oral Drugs Based on Molecular Surface Properties
Bergström, C. A. S., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., & Artursson, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020986i · Cited by 247
Characterization of emissions from burning incense
Jetter, J. J., Guo, Z., McBrian, J. A., & Flynn, M. R. (2002) · Science of The Total Environment · doi:10.1016/s0048-9697(02)00043-8 · Cited by 243
Drug Delivery via the Respiratory Tract
BYRON, P. R., & PATTON, J. S. (1994) · Journal of Aerosol Medicine · doi:10.1089/jam.1994.7.49 · Cited by 218
How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders?
Chew, N. Y. K., Tang, P., Chan, H.-K., & Raper, J. A. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9020-4 · Cited by 211
Drug Delivery: Principles and Applications
Wang, B., Siahaan, T. J., & Soltero, R. A. (2005) · Cited by 210
Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols
Dunber, C. A., Hickey, A. J., & Holzner, P. (1998) · KONA Powder and Particle Journal · doi:10.14356/kona.1998007 · Cited by 197
Self-citationNear‐infrared spectroscopy and imaging for the monitoring of powder blend homogeneity
El‐Hagrasy, A. S., Morris, H. R., D'Amico, F., Lodder, R. A., & Drennen, J. K. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1082 · Cited by 191
Mitchell, J. P., & Nagel, M. W. (2003) · Journal of Aerosol Medicine · doi:10.1089/089426803772455622 · Cited by 189
Concept, Strategies, and Feasibility of Noninvasive Insulin Delivery
Cefalu, W. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.239 · Cited by 182
Alternative sugars as potential carriers for dry powder inhalations
Steckel, H., & Bolzen, N. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.10.039 · Cited by 176
Advances in Pharmaceutical Sciences
GANDERTON, D. (1992) · Cited by 165
The inhalers of the future? A review of dry powder devices on the market today
Smith, I. J., & Parry-Billings, M. (2003) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/s1094-5539(02)00147-5 · Cited by 162
(2007) · Springer eBooks · doi:10.1007/3-540-69835-3 · Cited by 160
Tronde, A., Nordén, B. O., Marchner, H., Wendel, A., Lennernäs, H., & Bengtsson, U. H. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10386 · Cited by 158
van Gulijk, C., Marijnissen, J. C. M., Makkee, M., Moulijn, J. A., & Schmidt-Ott, A. (2004) · Journal of Aerosol Science · doi:10.1016/j.jaerosci.2003.11.004 · Cited by 151
Zanen, P., Go, L. T., & Lammers, J. J. (1996) · Thorax · doi:10.1136/thx.51.10.977 · Cited by 150
Analysis of the surface energy of pharmaceutical powders by inverse gas chromatography
Grimsey, I. M., Feeley, J. C., & York, P. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10060 · Cited by 131
A novel spray-drying technique to produce low density particles for pulmonary delivery
Steckel, H., & Brandes, H. G. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.03.010 · Cited by 130
Young, P. M., Cocconi, D., Colombo, P., Bettini, R., Price, R., Steele, D. F., & Tobyn, M. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702760345400 · Cited by 130
Drug Properties Affecting Aerosol Behavior
Suarez, S., & Hickey, A. J. (2000) · Respiratory Care · doi:10.1177/002013240004500609 · Cited by 128
Self-citationLatest advances in the development of dry powder inhalers
Ashurst, I., Malton, A., Prime, D., & SUMBY, B. S. (2000) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(00)00275-3 · Cited by 128
The Role of Particle Properties in Pharmaceutical Powder Inhalation Formulations
Chew, N. Y. K., & Chan, H. (2002) · Journal of Aerosol Medicine · doi:10.1089/089426802760292672 · Cited by 112
The optimal particle size for β-adrenergic aerosols in mild asthmatics
Zanen, P., Go, L. T., & Lammers, J. J. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90436-7 · Cited by 85
Behavior of Hygroscopic Pharmaceutical Aerosols and the Influence of Hydrophobic Additives
Hickey, A. J., & Martonen, T. B. (1993) · Pharmaceutical Research · doi:10.1023/a:1018952425107 · Cited by 83
Self-citationKawashima, Y., Serigano, T., Hino, T., Yamamoto, H., & Takeuchi, H. (1998) · Pharmaceutical Research · doi:10.1023/a:1011916930655 · Cited by 74
An empirical formula describing aerosol deposition in man for any particle size
Rudolf, G., Gebhart, J., Heyder, J., et al. (1986) · Journal of Aerosol Science · doi:10.1016/0021-8502(86)90103-5 · Cited by 68
Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug
Sethuraman, V. V., & Hickey, A. J. (2002) · AAPS PharmSciTech · doi:10.1208/pt030428 · Cited by 68
Self-citationDescriptors of irregular particle morphology and powder properties
Hickey, A. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00508-5 · Cited by 64
Self-citationPulmonary delivery of drugs for bone disorders
Patton, J. S. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00064-8 · Cited by 59
Fults, K., Miller, I. F., & Hickey, A. J. (1997) · Pharmaceutical Development and Technology · doi:10.3109/10837459709022610 · Cited by 55
Self-citationWhy Particle Size Should Affect Clinical Response to Inhaled Therapy
Howarth, P. H. (2001) · Journal of Aerosol Medicine · doi:10.1089/08942680150506312 · Cited by 54
The optimal particle size for parasympathicolytic aerosols in mild asthmatics
Zanen, P. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)00224-s · Cited by 53
A Guide to Pharmaceutical Particulate Science
Hickey, A. J., Crowder, T. M., Louey, M. D., & Orr, N. (2003) · CRC Press eBooks · doi:10.1201/9780203009673 · Cited by 52
Self-citationThe Design and Development of Inhalation Drug Delivery Systems
Crowder, T. M., & Atkins, P. J. (2003) · Drugs and the pharmaceutical sciences · doi:10.1201/9780203912898.ch9 · Cited by 52
Development of Liposomal Amphotericin B Dry Powder Inhaler Formulation
Shah, S. P., & Misra, A. R. (2004) · Drug Delivery · doi:10.1080/10717540490467375 · Cited by 50
The influence of inhaler selection on efficacy of asthma therapies
Barry, P. W., & O’Callaghan, C. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00083-8 · Cited by 39
Pulmonary disposition of budesonide from liposomal dry prowder inhaler
Joshi, M., & Nisra, A. N. (2001) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2001.23.10.677118 · Cited by 36
Use of a Jet Mill for Dispersing Dry Powder for Inhalation Studies
Cheng, Y., Märshall, T., Henderson, R. F., & Newton, G. J. (1985) · American Industrial Hygiene Association Journal · doi:10.1080/15298668591395148 · Cited by 34
Barnes, P. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2410004 · Cited by 15
Cited by
Formulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 791
Non-invasive delivery strategies for biologics
Anselmo, A. C., Gokarn, Y., & Mitragotri, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 665
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 520
Technological and practical challenges of dry powder inhalers and formulations
Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.04.004 · Cited by 303
Metadata
- Authors
- Telko, M. J., & Hickey, A. J.
- Venue
- Respiratory Care
- Publisher
- American Association for Respiratory Care
- Published
- 2005-09-01
- Volume
- 50
- Issue
- 9
- Pages
- 1209-1227
- ISSN
- 0020-1324 (ISSN-L)
- OpenAlex
- W1869177231
- Cited by
- 498
- References
- 72
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.